2025 Agenda

logologo

*All times are in EST

Apr

Fri 11

8:00AM -8:10AM

Meeting objectives and introduction
David Maloney & Frederick Locke

08:10AM -08:20AM

Welcome to the solid tumors day
Kedar Kirtane & Sarah Nikiforow

08:20AM -08:40AM

Keynote talk 1
How solid CAR-T targeting has evolved: Prasad Adusumilli

8:40AM -9:50AM

Session 1: CARs targeting cell surface proteins (part I)
Chairs: Susanne Baumeister & Kedar Kirtane

  • DLL3-CAR-T for SCLC: Adam Schoenfeld
  • GCC19 CAR-T therapy for refractory colorectal cancer: Overcoming challenges in expansion and persistence: Benjamin Schlechter
  • Updates on logic-gated CAR T-cell therapies in pancreatic cancer: Joel Randolph Hecht
  • An update on CAR T-cell therapy for breast and ovarian cancer: A long and winding road: Jennifer Specht

Panel discussion

9:50AM -10:40AM

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Joel Randolph Hecht & Jennifer Specht

  • CLDN6-targeted therapy with CAR-T cells +/- CARVac in relapsed germ cell tumors: Winfried Alsdorf
  • hALK.CAR T cells for relapsed/refractory neuroblastoma: Susanne Baumeister
  • Cell therapy advances in ovarian cancer: What we know and where we’re headed: Monica Avila

Panel discussion

10:40AM -11:10AM

Break

11:10AM -12:00PM

Session 3: T-cell engagers and TCRs
Chairs: Sarah Nikiforow & Benjamin Creelan

  • Afami-Cel in Metastatic Synovial Sarcoma: The 1st genetically engineered TCR therapy approved for a solid tumor: Mihaela Druta
  • Immunologic targeting of undruggable TP53 hotspot mutations through T cell receptor gene therapy: Mike Gormally
  • Targeting PRAME with TCR T cells first in melanoma then beyond: Jason Luke

Panel discussion

12:00PM -1:00PM

Lunch

1:00PM -1:50PM

Session 4: TILs across solid tumors
Chairs: Allison Betof Warner & Claire Roddie

  • Promising T cell targets in lung cancers: Trial updates: Benjamin Creelan
  • TIL therapy for GU malignancies: Michael Poch
  • Optimizing TIL therapy for melanoma & beyond: Allison Betof Warner

Panel discussion

1:50PM -3:10PM

Session 5: Novel technologies in solid tumors
Chairs: Sarah Nikiforow & Kedar Kirtane 

  • Talk title TBC (TanCAR-T): TBC
  • Genome-edited anti-GPC3 CAR for hepatoma: Marco Davila
  • Engineering myeloid cells for solid tumors and fibrosis: CARs and beyond: Michael Klichinsky
  • Cell and gene therapy: Current status and future directions – An industry perspective: Will Go
  • Advancing T cell therapies for solid cancers: Saul Priceman

Panel discussion

3:10PM -3:40PM

Break

3:40PM -4:15PM

Session 6: T-cell engagers and CARs in CLL
Chairs: David Maloney & Saar Gill

  • Optimizing liso-cel in CLL: Sequencing and combination strategies: Mazyar Shadman
  • Why bispecific antibodies may be the path forward in CLL: Alexey Danilov

Panel discussion

4:15PM -5:35PM

Session 7: CAR-T in ALL
Chairs: Claire Roddie & Saar Gill

  • Obecabtagene autoleucel: What have we learned from the FELIX study?: Claire Roddie
  • Talk title TBC (brexucabtagene autoleucel): Bijal Shah
  • CD19/CD22 CAR-T: Noelle Frey
  • SCRI‐CAR19 with CD19 T‐APC to prolong CAR T cell persistence: Rebecca Gardner
  • Improving clinical activity of CD5 CART in T-ALL: Maksim Mamonkin

Panel discussion

5:35PM -5:40PM

Day 1 conclusions

6:30PM -8:30PM

Welcome reception

Apr

Sat 12

8:30AM -8:35AM

Welcome to Day 2
Sarah Nikiforow & Yi Lin

8:35AM -8:55AM

Keynote talk 2
Frontiers in CAR T-cell therapy for autoimmune diseases: David Porter

8:55AM -10:15AM

Session 8: CAR therapy for autoimmune diseases
Chairs: David Porter & Everett Meyer

  • Early experience with the in vivo expanding anti-CD19 CAR-T, BMS-986353 for autoimmunity: Lazaros Lekakis
  • CD19 CAR NK-cell therapy for B-cell mediated autoimmune disease: David Shook
  • CAR T for dermatomyositis: Saurabh Dahiya
  • Antigen-specific treatment of myasthenia: Development of rat chimeric autoantibody receptor
    (CAAR) T cells to treat experimental autoimmune MuSK myasthenia: David Richman
  • State of the art with CAR therapy in MG: Ali Habib

Panel discussion

10:15AM -10:45AM

Session 9: How do we integrate autoimmune diseases into cell therapy centres?
Chairs: David Maloney & Sarah Nikiforow

Discussants: Frederick Locke, Everett Meyer, David Porter, Claire Roddie

10:45AM -11:15AM

Break

11:15AM -12:05PM

Session 10: Translational studies with T-cell engagers and CARs   
Chairs: Yi Lin & Saar Gill

  • Genomic determinants of resistance to anti BCMA and GPRC5D therapies: Francesco Maura
  • Metabolic fitness in CAR-T cells from earlier in the treatment course: Ciara Freeman
  • Insights into microbiome and microbial metabolites to augment CAR-T therapy: Maik Luu

Panel discussion

12:05PM -12:25PM

Keynote talk 3
Accelerating CAR T-cell therapeutics with small molecules and CRISPR2.0 gene-edits: Michael Hudecek

12:25PM -1:25PM

Lunch

1:25PM -2:35PM

Session 11: T-cell engagers for multiple myeloma
Chairs: Saad Usmani & TBC

  • Cevostamab: What, how and when?: Rakesh Popat
  • Teclistamab – the past was good, the future could be great!!: Tom Martin
  • Talk title TBC (talquetamab): Nisha Joseph
  • Multi-antigen targeting with trispecific antibodies in myeloma: JNJ-796353222: Sham Mailankody

Panel discussion

2:35PM -3:45PM

Session 12: CAR therapy for multiple myeloma
Chairs: Adam Sperling & Krina Patel

  • CAR-T cells in multiple myeloma: The evolving use of cilta-cel and ide-cel: Adam Sperling
  • Phase I / II summary of anito-cel for relapsed/refractory MM: Matthew Frigault
  • Arlocabtagene autoleucel in relapsed refractory multiple myeloma: Susan Bal
  • BCMA CAR-T clash of the Titans: Idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: Doris Hansen

Panel discussion

3:45PM -4:15PM

Break

4:15PM -4:45PM

Session 13: CAR therapy should come before T-cell engagers in multiple myeloma treatment sequencing
Chairs: Yi Lin & Doris Hansen

  • For: Krina Patel
  • Against: Sham Mailankody

Panel discussion

4:45PM -5:55PM

Session 14: Different approaches to CAR production in lymphoma
Chairs: David Maloney & Caron Jacobson

  • Rapcabtagene autoleucel for B-cell lymphomas and the potential role of CAR-T rapid manufacturing: Julio Chavez
  • Point-of-care manufacturing with Canadian-made CD19 CART, CLIC-1901: Natasha Kekre
  • ATALANTA-1: A Phase 1/2 trial of GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy with a 7-day vein-to-vein time, for the treatment of relapsed/refractory non-Hodgkin lymphoma: Caron Jacobson
  • Interim result multicenter Phase II trial of zamtocabtagene autoleucel, an non-cryopreserved anti-CD20/anti-CD19 CAR T cell product for relapsed, refractory DLBCL: Nirav Shah

Panel discussion

5:55PM -6:00PM

Day 2 conclusions

Faculty Dinner

Apr

Sun 13

8:30AM -8:35AM

Welcome to Day 3
Caron Jacobson & Frederick Locke

8:35AM -9:35AM

Session 15: Long-term follow-up and outcomes with CARs
Chairs: David Miklos & Elizabeth Budde

  • Long-term complications after CAR T-cell therapy: Michael Jain
  • Beyond CRS and ICANS: Non-relapse mortality after CAR T-cell therapy: Kai Rajeski
  • Catch me if you can: Lymphoma resistance to CAR T immunotherapy: Marco Ruella
  • Enhancing CAR T-cell activity and persistence with CAR-enhancer therapeutics: Mohamad Rashidian

Panel discussion

9:35AM -10:35AM

Session 16: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & Marion Subklewe

  • Back to the bench: Rethinking CAR T for AML: Marion Subklewe
  • Allogeneic, off-the-shelf, CAR T cells for AML: CB-012: Jae Park
  • Treatment of JMML and CMML with CLL-1 CAR-T cells +/- trametinib: Elliot Stieglitz
  • Immunotherapy in CALR-mutated myeloproliferative neoplasms: Approach with caution: Andrew Kuykendall

Panel discussion

10:35AM -10:55AM

Break

10:55AM -11:45PM

Session 17: What are the current challenges with CAR T in lymphoma and how can we address them?
Chairs: Caron Jacobson & David Miklos

  • Barriers: Why is CAR T-cell therapy not reaching its potential in heme malignancies?: Jason Westin
  • Sequencing novel treatment options in lymphoma: Gloria Iacoboni
  • Talk title TBC (perspective 3): Frederick Locke

Panel discussion

11:45PM -12:00PM

Keynote talk 4
Building a fast-paced outpatient IEC program: Elizabeth Budde

12:00PM -12:15PM

Working lunch

12:15PM -1:05PM

Session 18: T-cell engagers and CARs in lymphomas (part I)
Chairs: Tycel Phillips & Jennifer Crombie                                                                                                                                                     

  • Update on CB-010/allogeneic anti-CD19 CAR-T cell therapy: Mehdi Hamadani
  • Fixed-duration treatment with epcoritamab: Alexey Danilov
  • Bispecifics in lymphoma: Moving beyond CD20 targeting: Krish Patel

Panel discussion

1:05PM -1:55PM

Session 19: T-cell engagers and CARs in lymphomas (part II)
Chairs: Jason Westin & Gloria Iacoboni

  • Frontline & second-line DLBCL treatments – where are we in 2025?: Matt Lunning
  • Bispecific combinations in relapsed/refractory DLBCL: Jennifer Crombie
  • “Who’s on first”….Sequencing bispecifics with CAR-T in indolent lymphoma: Tycel Philips

Panel discussion

1:55PM -2:15PM

Keynote talk 5
Moving bispecifics and CAR T-cell therapies into the community setting: Tara Graff

2:15PM -2:45PM

Session 20: How to get CAR T-cell therapy into the community setting?
Chairs: Elizabeth Budde & Krish Patel  

Discussants: Tara Graff, Caron Jacobson, Frederick Locke

2:45PM -2:55PM

Meeting conclusions